Design of the MODIGLIA-NI trial and population
VTE
SECONDARY, VENOUS THROMBOEMBOLISM
This trial-based economic evaluation was based on MODIGLIA-NI, a non-inferiority, crossover, cluster-randomized trial conducted in 16 EDs in France and two in Spain. The study protocol has been previously published [The primary outcome in the efficacy trial was the percentage of failure of the diagnostic strategy (undetected VTE), defined as Venous thromboembolism (VTE) diagnosis at 3 months after exclusion of PE during the initial ED visit.The secondary end points were: chest imaging (CTPA or V˙ /Q˙ scan) ordered by ED physicians, ED length of stay, hospital admission following the ED visit, anticoagulant administration, all-cause mortality, and all-cause readmissions at 3 months.